154 related articles for article (PubMed ID: 10473022)
1. Palivizumab.
Scott LJ; Lamb HM
Drugs; 1999 Aug; 58(2):305-11; discussion 312-3. PubMed ID: 10473022
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
4. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
Scholz H
Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha I; McKoy N
Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
[TBL] [Abstract][Full Text] [Related]
7. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
9. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
12. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
[TBL] [Abstract][Full Text] [Related]
13. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
Robinson RF; Nahata MC
Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
18. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
[TBL] [Abstract][Full Text] [Related]
19. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
20. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
